RAGUSA, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 4.962
AS - Asia 2.491
EU - Europa 2.142
SA - Sud America 501
AF - Africa 143
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.251
Nazione #
US - Stati Uniti d'America 4.832
IT - Italia 909
SG - Singapore 774
CN - Cina 651
BR - Brasile 410
HK - Hong Kong 389
SE - Svezia 346
VN - Vietnam 284
DE - Germania 191
FR - Francia 113
BG - Bulgaria 110
GB - Regno Unito 106
FI - Finlandia 86
RU - Federazione Russa 80
CA - Canada 74
IN - India 67
NL - Olanda 57
IQ - Iraq 52
JP - Giappone 49
TR - Turchia 43
CI - Costa d'Avorio 41
BD - Bangladesh 39
MX - Messico 32
AR - Argentina 28
PL - Polonia 27
AT - Austria 23
SN - Senegal 22
NG - Nigeria 21
KR - Corea 20
ZA - Sudafrica 20
ES - Italia 17
EC - Ecuador 16
CO - Colombia 15
SA - Arabia Saudita 15
ID - Indonesia 14
CH - Svizzera 13
UA - Ucraina 13
PH - Filippine 12
MA - Marocco 11
UZ - Uzbekistan 10
CZ - Repubblica Ceca 9
PK - Pakistan 9
PY - Paraguay 9
VE - Venezuela 9
IE - Irlanda 8
AU - Australia 7
JO - Giordania 7
KE - Kenya 7
LT - Lituania 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
BY - Bielorussia 5
IL - Israele 5
IR - Iran 5
KZ - Kazakistan 5
AL - Albania 4
BE - Belgio 4
HN - Honduras 4
MY - Malesia 4
PS - Palestinian Territory 4
TH - Thailandia 4
TN - Tunisia 4
BB - Barbados 3
CL - Cile 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EG - Egitto 3
GR - Grecia 3
GT - Guatemala 3
NP - Nepal 3
OM - Oman 3
RO - Romania 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BH - Bahrain 2
BJ - Benin 2
BN - Brunei Darussalam 2
BS - Bahamas 2
DK - Danimarca 2
ET - Etiopia 2
EU - Europa 2
GE - Georgia 2
GY - Guiana 2
JM - Giamaica 2
PE - Perù 2
RS - Serbia 2
AM - Armenia 1
BW - Botswana 1
CY - Cipro 1
EE - Estonia 1
FJ - Figi 1
GA - Gabon 1
GH - Ghana 1
HR - Croazia 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
Totale 10.241
Città #
Ashburn 580
Dallas 523
Singapore 463
Fairfield 400
Santa Clara 383
Hong Kong 378
San Jose 378
Milan 207
Woodbridge 206
Pisa 188
Chandler 179
Seattle 174
Shanghai 174
Cambridge 149
Houston 144
Wilmington 132
Serra 127
Council Bluffs 121
Sofia 110
Los Angeles 109
New York 108
Beijing 88
Munich 78
Boardman 74
Ho Chi Minh City 73
Princeton 72
Ann Arbor 58
Helsinki 53
Florence 48
London 48
Lauterbourg 47
Rome 47
Lawrence 46
Tokyo 45
Frankfurt am Main 42
Medford 42
Abidjan 41
Hanoi 39
Hefei 35
Redondo Beach 33
São Paulo 32
Buffalo 29
Dong Ket 27
Boulder 26
Turku 24
Redwood City 23
San Diego 23
Dakar 22
Columbus 21
Istanbul 21
Paris 21
Warsaw 21
Bremen 20
Seoul 20
Des Moines 19
Fuzhou 19
Ottawa 19
Lagos 18
Nuremberg 18
Sulaymaniyah 18
Baghdad 16
Nanjing 16
Ogden 16
Livorno 15
Vienna 15
Phoenix 14
Rio de Janeiro 14
Amsterdam 13
Carrara 13
Montreal 13
Chennai 12
Da Nang 12
Dearborn 12
Johannesburg 12
Orem 12
Toronto 12
Washington 12
Brasília 11
Denver 11
Norwalk 11
The Dalles 11
Baltimore 10
Brooklyn 10
Changsha 10
Chicago 10
Düsseldorf 10
Guangzhou 10
Haiphong 10
Hyderabad 10
Manchester 9
Memphis 9
Quanzhou 9
Tashkent 9
Zurich 9
Cascina 8
Dhaka 8
Dublin 8
Figino 8
Mexico City 8
Amman 7
Totale 7.128
Nome #
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 254
Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy 247
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 237
Molecular testing in the diagnosis of differentiated thyroid carcinomas 226
Sunitinib in the treatment of thyroid cancer 219
The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases 206
Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study 200
THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors 192
New insight in endocrine-related adverse events associated to immune checkpoint blockade 191
Novel therapies for thyroid autoimmune diseases: An update 190
Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy 190
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer 189
Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture 187
Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide 183
Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses 180
Novel treatments for anaplastic thyroid carcinoma 174
Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells 166
Myo-inositol in autoimmune thyroiditis, and hypothyroidism 165
The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series 163
Immunomodulation of CXCL10 secretion by hepatitis C virus: Could CXCL10 be a prognostic marker of chronic hepatitis C? 163
Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy 163
Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells 162
The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine 161
Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update 160
Chemokines in thyroid autoimmunity 159
Immune and inflammatory cells in thyroid cancer microenvironment 157
Novel treatment options for anaplastic thyroid cancer 156
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration 156
Nutraceuticals in thyroidology: A review of in vitro, and in vivo animal studies 156
Thyroid Autoimmunity and SARS-CoV-2 Infection 153
Recent advances in precision medicine for the treatment of anaplastic thyroid cancer 153
CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide 151
Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN-ALK Fusion In Vitro 149
Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer 148
Precision Medicine in Autoimmune Thyroiditis and Hypothyroidism 147
Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin 146
The protective effect of myo-inositol on human thyrocytes 145
Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy 145
Antineoplastic effect of doxorubizen in vitro in continuous and primary human anaplastic thyroid cancer cells 143
Chemokines in hyperthyroidism 143
Hypothyroidism and metabolic cardiovascular disease 142
Lactose intolerance and levothyroxine malabsorption: a review of the literature and report of a series of patients treated with liquid L-T4 without lactose 141
Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies 141
Autoimmune endocrine dysfunctions associated with cancer immunotherapies 140
Molecular features of aggressive thyroid cancer 138
Molecular targets of tyrosine kinase inhibitors in thyroid cancer 136
Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis 135
Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer 135
Thyroid Metastasis from Primary Breast Cancer 133
Liquid L-T4 therapy in hypothyroid patients with gastric diseases, an observational study 133
Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases 124
Graves' disease induced by IFN-β1a therapy: A case report, review of literature and new insights into the pathogenesis 121
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 118
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 118
Simultaneous Occurrence of Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma: A Case Series with Literature Review 116
null 115
Teprotumumab for the treatment of thyroid eye disease 114
Precision Medicine in Graves’ Disease and Ophthalmopathy 113
Endocrine disruptors and thyroid autoimmunity 105
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 104
Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series 103
Evaluating vandetanib in the treatment of medullary thyroid cancer: Patient-reported outcomes 103
L-T4 Therapy in Enteric Malabsorptive Disorders 102
null 87
Graves' Disease Following SARS-CoV-2 Vaccination: A Systematic Review 86
Thyroid autoimmune disorders and cancer 85
null 75
Myoinositol in Autoimmune Thyroiditis 74
Th1 chemokines in autoimmune endocrine disorders 69
Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity 42
The pyrazolo[3,4-d]pyrimidine derivative CLM24 has an antineoplastic effect in aggressive dedifferentiated thyroid cancer in vitro 38
Autoimmune Thyroid Diseases and Epigenetics 32
Dermatomyositis and MIG 30
MIG chemokine in systemic sclerosis. MIG in Systemic sclerosis 30
Mesothelioma and interferon-γ-dependent chemokine IP-10 27
Sarcoidosis and the Th1 chemokine MIG 26
Th1 chemokines in ulcerative colitis 26
IP-10 in occupational asthma: review of the literature and case-control study 25
Sarcoidosis and Th1 chemokines 24
Nanoparticles in Thyroid Autoimmunity: Diagnostic and Therapeutic Applications 21
Totale 10.602
Categoria #
all - tutte 31.256
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.256


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022715 13 14 28 47 109 92 32 33 67 59 56 165
2022/2023770 118 106 67 37 68 92 34 46 122 5 62 13
2023/2024836 67 78 121 97 120 135 55 24 12 17 38 72
2024/20252.627 119 72 72 140 259 310 257 124 149 283 307 535
2025/20263.722 259 386 556 376 314 261 522 168 200 399 107 174
2026/202746 46 0 0 0 0 0 0 0 0 0 0 0
Totale 10.602